IL13 and chronic rhinosinusitis with nasal polyps: “Biologics”, which selectively target the type 2 inflammatory cascade by binding to specific interleukins such as IL-4, IL-5, and IL-13 or their respective receptors, is a reliable treatment option for all those CRSwNP patients who experience failure of conventional therapy during follow-up [5,34].